Acotiamide, a novel gastroprokinetic for the treatment of patients with functional dyspepsia: postprandial distress syndrome

References

• Piessevaux H, De Winter B, Louis E et al. Dyspeptic symptoms in the general population: a factor and cluster analysis of symptom groupings. Neurogastroenterol. Motil. 21(4), 378–388 (2009).
   PubMed Web of Science ®Google Scholar
• Tack J, Bisschops R, Sarnelli G. Pathophysiology and treatment of functional dyspepsia. Gastroenterology 127(4), 1239–1255 (2004).
   PubMed Web of Science ®Google Scholar
• Kindt S, Tack J. Impaired gastric accommodation and its role in dyspepsia. Gut 55(12), 1685–1691 (2006).
   PubMed Web of Science ®Google Scholar
• Van Oudenhove L, Vandenberghe J, Geeraerts B et al. Determinants of symptoms in functional dyspepsia: gastric sensorimotor function, psychosocial factors or somatisation? Gut 57(12), 1666–1673 (2008).
   PubMed Web of Science ®Google Scholar
• Kindt S, Van Oudenhove L, Mispelon L, Caenepeel P, Arts J, Tack J. Longitudinal and cross-sectional factors associated with long-term clinical course in functional dyspepsia: a 5-year follow-up study. Am. J. Gastroenterol. 106(2), 340–348 (2011).
   PubMed Web of Science ®Google Scholar
• Tack J, Janssen P. Emerging drugs for functional dyspepsia. Expert Opin. Emerg. Drugs 16(2), 283–292 (2011).
   PubMed Web of Science ®Google Scholar
• Talley NJ, Colin-Jones D, Koch KL, Nyren O, Stanghellini V. Functional dyspepsia. A classification with guidelines for diagnosis and management. Gastroenterol. Int. 4, 145–160 (1991).
   Google Scholar
• Talley NJ, Stanghellini V, Heading RC, Koch KL, Malagelada JR, Tytgat GN. Functional gastroduodenal disorders. Gut. 45(Suppl. 2), II37–II42 (1999).
   PubMedGoogle Scholar
• Tack J, Talley NJ, Camilleri M et al. Functional gastroduodenal disorders. Gastroenterology 130(5), 1466–1479 (2006).
   PubMed Web of Science ®Google Scholar
• Talley NJ, Ruff K, Jiang X, Jung HK. The Rome III Classification of dyspepsia: will it help research? Dig. Dis. 26(3), 203–209 (2008).
   PubMed Web of Science ®Google Scholar
• Tack J, Masaoka T, Janssen P. Functional dyspepsia. Curr. Opin. Gastroenterol. 27(6), 549–557 (2011).
   PubMed Web of Science ®Google Scholar
• Hallerbäck BI, Bommelaer G, Bredberg E et al. Dose finding study of mosapride in functional dyspepsia: a placebo-controlled, randomized study. Aliment. Pharmacol. Ther. 16(5), 959–967 (2002).
   PubMed Web of Science ®Google Scholar
• Holtmann G, Talley NJ, Liebregts T, Adam B, Parow C. A placebo-controlled trial of itopride in functional dyspepsia. N. Engl. J. Med. 354(8), 832–840 (2006).
   PubMed Web of Science ®Google Scholar
• Talley NJ, Tack J, Ptak T, Gupta R, Giguère M. Itopride in functional dyspepsia: results of two Phase III multicentre, randomised, double-blind, placebo-controlled trials. Gut 57(6), 740–746 (2008).
   PubMed Web of Science ®Google Scholar
• Ogishima M, Kaibara M, Ueki S, Kurimoto T, Taniyama K. Z-338 facilitates acetylcholine release from enteric neurons due to blockade of muscarinic autoreceptors in guinea pig stomach. J. Pharmacol. Exp. Ther. 294(1), 33–37 (2000).
   PubMed Web of Science ®Google Scholar
• Nakajima T, Nawata H, Ito Y. Z-338, a newly synthetized carboxyamide derivative, stimulates gastric motility through enhancing the excitatory neurotransmission. J. Smooth Muscle Res. 36(2), 69–81 (2000).
   PubMedGoogle Scholar
• Doi Y, Murasaki O, Kaibara M et al. Characterization of functional effects of Z-338, a novel gastroprokinetic agent, on the muscarinic M1, M2, and M3 receptors expressed in Xenopus oocytes. Eur. J. Pharmacol. 505(1–3), 31–35 (2004).
   PubMed Web of Science ®Google Scholar
• Morita H, Abe K, Ito Y, Inoue R. Possible involvement of M5 muscarinic receptor in the enhancing actions of the novel gastroprokinetic agent Z-338 on nifedipine-sensitive voltage-dependent Ca2+ currents in guinea pig stomach. Jpn. J. Pharmacol. 89(4), 356–365 (2002).
   PubMedGoogle Scholar
• Kawachi M, Matsunaga Y, Tanaka T et al. Acotiamide hydrochloride (Z-338) enhances gastric motility and emptying by inhibiting acetylcholinesterase activity in rats. Eur. J. Pharmacol. 666(1–3), 218–225 (2011).
   PubMed Web of Science ®Google Scholar
• Matsunaga Y, Tanaka T, Yoshinaga K et al. Acotiamide hydrochloride (Z-338), a new selective acetylcholinesterase inhibitor, enhances gastric motility without prolonging QT interval in dogs: comparison with cisapride, itopride, and mosapride. J. Pharmacol. Exp. Ther. 336(3), 791–800 (2011).
   PubMed Web of Science ®Google Scholar
• Seto K, Sasaki T, Katsunuma K, Kobayashi N, Tanaka K, Tack J. Acotiamide hydrochloride (Z-338), a novel prokinetic agent, restores delayed gastric emptying and feeding inhibition induced by restraint stress in rats. Neurogastroenterol. Motil. 20(9), 1051–1059 (2008).
   PubMed Web of Science ®Google Scholar
• Kobayashi N, Seto K, Sasaki T, et al. Acotiamide (Z-338), a novel gastroprokinetic agent for the treatment of functional dyspepsia, restores delayed gastric emptying induced by restraint stress via the vagal afferent pathway in rats. Gastroenterology 140, S603–S603 (2011).
   Google Scholar
• Price CJ, Hoyda TD, Ferguson AV. The area postrema: a brain monitor and integrator of systemic autonomic state. Neuroscientist 14(2), 182–194 (2008).
   PubMed Web of Science ®Google Scholar
• Kawachi M, Hori N, Takei M, Kurimoto T, Akaike N, Ito Y. Gastric relaxation induced by electrical and chemical stimulation of the area postrema in the rat. Gen. Physiol. Biophys. 27(4), 243–252 (2008).
   PubMed Web of Science ®Google Scholar
• Akaike H, Jang II, Hori N, Ogawa S, Ito Y, Akaike N. Effects of Z-338, a novel gastroprokinetic agent, on the actions of excitatory and inhibitory neurotransmitters on neurons in area postrema. J. Smooth Muscle Res. 46(1), 31–47 (2010).
   PubMedGoogle Scholar
• Tack J, Masclee A, Heading R et al. A dose-ranging, placebo-controlled, pilot trial of acotiamide in patients with functional dyspepsia. Neurogastroenterol. Motil. 21(3), 272–280 (2009).
   PubMed Web of Science ®Google Scholar
• Oliver SD, Ward C, Ward J, Kato H, Saito Y, Furuta S. Z-338: Phase I, single and multiple oral dose, safety, tolerability and pharmacokinetic studies in healthy male subjects. Abstracts of the Joint Meeting of VII World Conference on Clinical Pharmacology and Therapeutics IUPHAR – Division of Clinical Pharmacology & 4th Congress of the European Association for Clinical Pharmacology and Therapeutics. 244 (2000).
   Google Scholar
• Adam B, Liebregts T, Zschau NB, et al. Z-338 improves meal-induced symptoms in functional dyspepsia: a double-blind, randomized, placebo controlled crossover study. Gastroenterology 136, A535 (2009).
   Web of Science ®Google Scholar
• Kusunoki H, Haruma K, Manabe N et al. Therapeutic efficacy of acotiamide in patients with functional dyspepsia based on enhanced postprandial gastric accommodation and emptying: randomized controlled study evaluation by real-time ultrasonography. Neurogastroenterol. Motil. 24(6), 540–545, e250 (2012).
   PubMed Web of Science ®Google Scholar
• Matsueda K, Hongo M, Sasaki D, et al. Therapeutic efficacy of novel agent (Z-338) in functional dyspepsia. Gastroenterology 128, A467 (2005).
   Web of Science ®Google Scholar
• Tack JF, Talley NJ, Kowalski DL, Borton MA, Barve A. Influence of PPI run-in, pH monitoring and nutrient tolerance on efficacy outcomes of acotiamide hydrochloride (YM443), a novel acetylcholine esterase inhibitor, in functional dyspepsia. Gastroenterology 134, A143 (2008).
   Web of Science ®Google Scholar
• Talley NJ, Tack JF, Kowalski DL, Borton MA, Barve A. A novel acetylcholine esterase inhibitor acotiamide hydrochloride (YM443) in functional dyspepsia: Efficacy in a randomized, double-blind, placebo-controlled dose ranging trial. Gastroenterology 134, A157–A158 (2008).
   Google Scholar
• Matsueda K, Hongo M, Tack J, Aoki H, Saito Y, Kato H. Clinical trial: dose-dependent therapeutic efficacy of acotiamide hydrochloride (Z-338) in patients with functional dyspepsia – 100 mg t.i.d. is an optimal dosage. Neurogastroenterol. Motil. 22(6), 618–e173 (2010).
   PubMed Web of Science ®Google Scholar
• Tack JF, Stanghellini V, Hohmann G, et al. Efficacy and safety study of acotiamide (Z-338) in European patients with functional dyspepsia. Gastroenterology 140, S805–S805 (2011).
   Google Scholar
• Matsueda K, Hongo M, Tack J, Saito Y, Kato H. A placebo-controlled trial of acotiamide for meal-related symptoms of functional dyspepsia. Gut 61(6), 821–828 (2012).
   PubMed Web of Science ®Google Scholar
• Matsueda K, Hongo M, Ushijima S, Akiho H. A long-term study of acotiamide in patients with functional dyspepsia: results from an open-label Phase III trial in Japan on efficacy, safety and pattern of administration. Digestion 84(4), 261–268 (2011).
   PubMed Web of Science ®Google Scholar
• Suzuki H, Hibi T. Acotiamide (Z-338) as a possible candidate for the treatment of functional dyspepsia. Neurogastroenterol. Motil. 22(6), 595–599 (2010).
   PubMed Web of Science ®Google Scholar